Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases: Clinical impact

Oncology (Switzerland)

Volumn 84, Issue 3, 2013, Pages 150-157

  Ibrahim, Toni ^a   Farolfi, Alberto ^a   Scarpi, Emanuela ^b   Mercatali, Laura ^a   Medri, Laura ^c   Ricci, Marianna ^a   Nanni, Oriana ^b   Serra, Luigi ^c   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b Unit of Biostatistics and Clinical Trials   (United States)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Advanced breast cancer prognosis; Discordance; Hormone receptors; Human epidermal growth factor receptor 2; Ki67; Metastasis biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PLEURA METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN METASTASIS; BREAST METASTASIS; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CELL PROLIFERATION; CYTOLOGY; ELECTRONIC MEDICAL RECORD; MIDDLE AGED; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871233229     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000345795     Document Type: Article

References (32)

1. Payne SJ, Bowen RL, Jones JL, Wells CA: Predictive markers in breast cancer -the present. Histopathology 2008; 52: 82-90. (Pubitemid 350265187)
2. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20: 1499-1504.
3. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nole F, Munzone E, Goldhirsch A: Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011; 22: 2227-2233.
4. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 587-592.
5. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D: Quantitative analysis of changes in ER, PR and HER-2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010; 21: 1254-1261.
6. Santinelli A, Pisa E, Stramazzotti D, Fabris G: HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122: 999-1004. (Pubitemid 351213996)
7. Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schötzau A, Kononen J, Sauter G: Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst Aug 2001; 93: 1141-1146. (Pubitemid 32780965)
8. Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Fréneaux P, Diéras V, Thiéry JP, Sastre-Garau X: HER-2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER-2 therapy management? Br J Cancer 2007; 96: 654-659.
9. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico R, Jovic G, Conte P: Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 838-844.
10. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20: 1953-1958.
11. Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: 1763-1769. (Pubitemid 40563246)
12. Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD: HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat 2011; 129: 659-674.
13. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, Mc-Shane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
14. Landis JR, Kock GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174. (Pubitemid 8054849)
15. Kaplan EL, Meier P: Non parametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
16. Lawless JS: Statistical Models and Methods for Life-Time Data. New York, Wiley, 1982.
17. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ: Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
18. Mengel M, von Wasielewski R, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H, International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 22: 1656-1664.
19. Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, Fernö M: The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010; 23: 251-259.
20. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
21. De Censi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B: Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 2011; 22: 582-587.
22. De Censi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien E, Lien E, Luini A, Pelosi G, Bonanni B: Ki-67 expression after tamoxifen given preoperatively predicts disease free survival and overall survival in women with operable ER-positive breast cancer. Cancer Res 2009; 69: 406.
23. Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 2011; 29: 1531-1538.
24. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
25. Demicheli R, Ardoino I, Boracchi P, Coradini D, Agresti R, Ferraris C, Gennaro M, Hrushesky WJ, Biganzoli E: Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 2010; 10: 656.
26. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-98.
27. Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Lindström L, Bergh J: HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011; 125: 553-561.
28. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30: 593-599.
29. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V: Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis. Ann Oncol 2012, E-pub ahead of print.
30. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N: Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 2011; 9: 131.
31. Pusztai L, Viale G, Kelly CM, Hudis CA: Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010; 15: 1164-1168.
32. Prat A, Perou CM: Mammary development meets cancer genomics. Nat Med 2009; 15: 842-844.